DPP-IV inhibitor used in renal failure:
**Core Concept**
DPP-IV inhibitors are a class of oral antidiabetic drugs used to treat type 2 diabetes mellitus by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). They work by increasing the levels of incretin hormones, which in turn stimulate the release of insulin and decrease the release of glucagon. In patients with renal failure, certain DPP-IV inhibitors may be contraindicated due to their pharmacokinetics.
**Why the Correct Answer is Right**
Sitagliptin is a DPP-IV inhibitor that is specifically designed to be renally cleared. However, unlike other DPP-IV inhibitors, sitagliptin is primarily excreted via the bile into the feces, with a small fraction being excreted in the urine. This unique pharmacokinetic profile makes sitagliptin a suitable option for patients with renal failure. In contrast, other DPP-IV inhibitors like saxagliptin and linagliptin are also excreted in the urine, but their doses need to be adjusted in patients with severe renal impairment.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is not mentioned in the context of the question.
**Option B:** Saxagliptin is another DPP-IV inhibitor, but its dose needs to be adjusted in patients with severe renal impairment, making it less suitable for patients with renal failure.
**Option C:** Linagliptin is a DPP-IV inhibitor that is primarily cleared via the liver and does not require dose adjustment in patients with renal impairment, but it is not the most suitable option for patients with renal failure.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that not all DPP-IV inhibitors are created equal, and their pharmacokinetics vary significantly. Sitagliptin's unique profile makes it a preferred option for patients with renal failure, but clinicians should always consider the individual patient's renal function and adjust doses accordingly.
**Correct Answer:** C. Linagliptin is primarily cleared via the liver and does not require dose adjustment in patients with renal impairment.